GTHX — G1 Therapeutics Share Price
0.000.00%
Last trade - 00:00- $377.22m
- $360.81m
- $82.51m
- 51
- 10
- 94
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.34 | ||
| Price to Tang. Book | 15.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.91% | ||
| Return on Equity | -109.01% | ||
| Operating Margin | -65.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 45.28 | 31.48 | 51.3 | 82.51 | 73.54 | 94.49 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Directors
- Garry Nicholson NEC (66)
- John Bailey PRE (56)
- Jennifer Moses CFO (46)
- Terry Murdock COO (61)
- Rajesh Malik SVP (62)
- Andrew Perry CCO
- James Hanson GCN (49)
- Mark Avagliano OTH (45)
- Mark Velleca DRC (57)
- Willie Deese IND (66)
- Glenn Muir IND (62)
- Cynthia Schwalm IND (61)
- Alicia Secor IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 19th, 2008
- Public Since
- May 17th, 2017
- No. of Shareholders
- 10
- No. of Employees
- 100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 52,758,191
- Address
- 700 Park Offices Drive, Suite 200, RESEARCH TRIANGLE PARK, 27709
- Web
- https://www.g1therapeutics.com/
- Phone
- +1 9192139835
- Contact
- William Roberts
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for GTHX
Q4 2024 G1 Therapeutics Inc Earnings Release
Similar to GTHX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the G1 Therapeutics share price?
As of Today at 21:14 UTC, shares in G1 Therapeutics are trading at $7.15. This share price information is delayed by 15 minutes.
How has the G1 Therapeutics share price performed this year?
Shares in G1 Therapeutics last closed at $7.15 and the price had moved by +346.88% over the past 365 days. In terms of relative price strength the G1 Therapeutics share price has outperformed the S&P500 Index by +253.49% over the past year.
What are the analyst and broker recommendations for G1 Therapeutics?
The overall consensus recommendation for G1 Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the G1 Therapeutics dividend yield?
G1 Therapeutics does not currently pay a dividend.
Does G1 Therapeutics pay a dividend?
G1 Therapeutics does not currently pay a dividend.
When does G1 Therapeutics next pay dividends?
G1 Therapeutics does not currently pay a dividend.
How do I buy G1 Therapeutics shares?
To buy shares in G1 Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of G1 Therapeutics?
As of the previous close price of $7.15, shares in G1 Therapeutics had a market capitalisation of $377.22m.
Where are G1 Therapeutics shares listed?
Here are the trading details for G1 Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GTHX
What kind of share is G1 Therapeutics?
Based on an overall assessment of its quality, value and momentum G1 Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a G1 Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the G1 Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like G1 Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +110.43%.
As of the last closing price of $7.15, shares in G1 Therapeutics were trading +79.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the G1 Therapeutics PE Ratio?
The G1 Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of G1 Therapeutics?
G1 Therapeutics' management team is headed by:
- Garry Nicholson - NEC
- John Bailey - PRE
- Jennifer Moses - CFO
- Terry Murdock - COO
- Rajesh Malik - SVP
- Andrew Perry - CCO
- James Hanson - GCN
- Mark Avagliano - OTH
- Mark Velleca - DRC
- Willie Deese - IND
- Glenn Muir - IND
- Cynthia Schwalm - IND
- Alicia Secor - IND